Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. Until today this year the stock’s price performance recorded a decrease of -22.92%. However, over the last six months, the performance has been stronger by -44.85%. The price of CTKB decreased -22.08% over the last 30 days. And in the last five days, it has surged by 8.10%.
Cytek Biosciences Inc. (CTKB) stock is currently valued at $7.87. During the last session, the stock experienced a remarkable rise, reaching $7.935 after opening at $7.08. The stock briefly dropped to $6.96 before ultimately closing at $7.03.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
The market performance of Cytek Biosciences Inc.’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $16.05 on 08/11/22, while the lowest value for the same duration was $6.45 on 05/18/23.
52-week price history of CTKB Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Cytek Biosciences Inc.’s current trading price is -50.97% away from its 52-week high, while its distance from the 52-week low is 22.02%. The stock’s price range during this time has been between $6.45 and $16.05. The trading volume for the Healthcare sector company’s shares reached about 1.23 million for the day, which was lower than the average daily volume of 1.35 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Cytek Biosciences Inc. (CTKB) has experienced a quarterly decline of -28.26% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.02B and boasts a workforce of 682 employees.
Cytek Biosciences Inc.: Analysts’ Ratings Unveiled
As of right now, 2 analysts are rating Cytek Biosciences Inc. as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 10.33, with a change in price of -1.85. Similarly, Cytek Biosciences Inc. recorded 1,104,012 in trading volume during the last 100 days, posting a change of -19.03%.
CTKB’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CTKB stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.00.
CTKB Stock Stochastic Average
Today, Cytek Biosciences Inc.’s raw stochastic average for the past 50 days stands at 24.23%, indicating a rise from the raw stochastic average of the last 20 days, which was 24.23%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 12.74% and 7.21% respectively.